I have provided some refrences but you can use others as well
The trials of vaccines against human papillomavirus showed a very high efficacy. However this was against lesions that are intermediate stage to cervical cancer. Is there a role for modelling here in assessing impacts on cervical cancer?
There’s really a few things to explore here – for instance how confident can we be of protection against cervical cancer when the trial couldn’t assess outcome directly? Could modelling help with this? And if so – what sort of things might affect the vaccine impact?
Refrences
Garnett GP, Journal of Infectious Diseases 2005 191: S97-S106 and Tabrizi S, et. al. Lancet Infectious Diseases 2014 14(10) 958-966
Regan D et. al. Sexual Health 4(3) 147–163 and Kulasingam S et. al. Sexual Health. 2007 Sep;4(3):165-75.
[1] Regan, DG et al (2007). Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sexual Health 4: 147–163. http://dx.doi.org/10.1071/SH07042
Last Completed Projects
| topic title | academic level | Writer | delivered |
|---|